Key Takeaways
- • Implicity, an AI-driven cardiac remote monitoring company, has raised $40 million in a funding round led by IRIS, a European tech growth capital firm, with co-investment from Five Arrows (Rothschild & Co.'s alternative assets division).
- • The funding validates market demand for artificial intelligence applications in remote cardiac care and monitoring, a growing segment within digital health infrastructure.
- • The lead investors represent institutional capital focused on European technology growth, signaling confidence in Implicity's expansion trajectory and competitive positioning in the cardiac monitoring space.
- • The round provides runway for product development, market expansion, and potential M&A activity within the remote patient monitoring sector.
Summary
Implicity, a Cambridge-based company specializing in AI-driven cardiac remote monitoring solutions, has completed a $40 million funding round, the company announced on September 11, 2026. The round was led by IRIS, a European technology growth capital firm, with participation from Five Arrows, the alternative assets management division of Rothschild & Co.
The funding reflects institutional investor appetite for artificial intelligence applications in digital health, particularly in remote monitoring segments where regulatory pathways are increasingly defined and reimbursement models are maturing. Cardiac monitoring represents a substantial addressable market within remote patient monitoring, driven by aging demographics and healthcare systems' incentives to shift treatment from inpatient to outpatient settings.
The participation of both IRIS and Five Arrows indicates strong institutional validation. IRIS's involvement underscores European investor interest in AI-enabled healthcare infrastructure, while Rothschild's alternative assets arm signals the deal's positioning within a broader alternative investment thesis around healthcare innovation and operational efficiency. This capital structure suggests a growth-stage trajectory rather than early-stage funding, indicating Implicity has demonstrated product-market fit and viable commercialization pathways.
The proceeds will likely support scaling operations, expanding clinical evidence through real-world data studies, and potentially pursuing geographic expansion or acquisitions to consolidate market position within the competitive remote cardiac monitoring sector.
The funding reflects institutional investor appetite for artificial intelligence applications in digital health, particularly in remote monitoring segments where regulatory pathways are increasingly defined and reimbursement models are maturing. Cardiac monitoring represents a substantial addressable market within remote patient monitoring, driven by aging demographics and healthcare systems' incentives to shift treatment from inpatient to outpatient settings.
The participation of both IRIS and Five Arrows indicates strong institutional validation. IRIS's involvement underscores European investor interest in AI-enabled healthcare infrastructure, while Rothschild's alternative assets arm signals the deal's positioning within a broader alternative investment thesis around healthcare innovation and operational efficiency. This capital structure suggests a growth-stage trajectory rather than early-stage funding, indicating Implicity has demonstrated product-market fit and viable commercialization pathways.
The proceeds will likely support scaling operations, expanding clinical evidence through real-world data studies, and potentially pursuing geographic expansion or acquisitions to consolidate market position within the competitive remote cardiac monitoring sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.